

Michigan Pharmacy and Therapeutics Committee
Meeting of September 9, 2008, 6PM
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Introductions and Approval of Minutes of June 3, 2008 meeting

Dr. Nedd introduced Paul Thill, PharmD, newest appointee to the Committee.
Other members present: Khan Nedd, MD; Jon Arend, PharmD; Rockelle Rogers, MD; James Dillon, MD; Ron Bradley, DO; J. Fiechtner, MD; Neil Dorfman, RPh; G. Perri, MD. Members absent: Erin Inman, PharmD; Paul Dake, MD. Staff present: Annette Paul, RPh, First Health Services Corporation; Debera Eggleston, MD; Nina Mattarella, MD; Jacqueline Coleman; Sean Bodell; Heather Slawinski. Guest: Karen Jonas, RPh, DUR Board member
The draft minutes of the June 3, 2008 meeting were approved as final.

New Drugs

Following review and discussion, the Committee recommends to the Department the following:

Omnaris; add to the Michigan Pharmaceutical Product List (MPPL) and to the Preferred Drug List (PDL) in the class “Nasal Steroids” with prior authorization
Pristiq; add to the MPPL
Voltaren gel; add to the MPPL with prior authorization
Treximet; add to the MPPL and to the PDL class “Serotonin Receptor Agonists”; review utilization data at six months

Line Extensions

Fenoglide; add to the MPPL and to the PDL class “Lipotropics-Non Statins: Fibric Acid Derivatives” with prior authorization
Protonix packets; add to the MPPL and to the PDL class “Proton Pump Inhibitors” with prior authorization
Luvox CR; add to the MPPL
Lamisil packets; add to the MPPL and to the PDL class “Antifungals-Onychomycosis” with a clinical edit as exists for other Lamisil products
Dermotic; add to the MPPL

Review of Preferred Drug List Classes

Following review and discussion, the Committee recommends to the Department the following:

Diabetes:

For the Preferred Drug List classes
Amylin Analogs
Secretin Mimetics
Basal Insulins
Rapid Acting Insulins
Insulin Mixes
Traditional Insulins
Oral Hypoglycemics-Alpha Glucosidase Inhibitors

Oral Hypoglycemics-Biguanides
Oral Hypoglycemics-Combinations
Oral Hypoglycemics-DPP4 Inhibitors
Oral Hypoglycemics-Meglitinides
Oral Hypoglycemics-2nd Generation Sulfonylureas
Oral Hypoglycemics-Thiazolidinediones
No changes to the current classifications of the drug products listed

Gastrointestinal:

No changes to the current classification of drug products in the following classes listed on the Preferred Drug List:

Nausea Agents-Oral
Substance P Receptor Agonist
Proton Pump Inhibitors
Laxatives, New Generation
Ulcerative Colitis, Oral

Miscellaneous:

For the following drug classes,
Glaucoma-Alpha2 Adrenergics
Glaucoma-Beta Blockers
Glaucoma-Prostaglandin Inhibitors
Glaucoma-Carbonic Anhydrase Inhibitors
Ophthalmic Antihistamines
Ophthalmic Fluoroquinolones
Ophthalmic Mast Cell Stabilizers
Ophthalmic NSAIDS
Growth Hormones
Osteoporosis Agents, Bisphosphonates
Osteoporosis Agents, Other
Osteoporosis Agents, SERMS
Serotonin Receptor Agonists
Urinary Tract Antispasmodics
Topical Immunomodulators
Electrolyte Depleters
Alpha Blockers for BPH
Agents for Multiple Sclerosis
Non-Ergot Dopamine Receptor Agonists
Biologic Immunomodulators
Hematopoietic Agents
Low Molecular Weight Heparins
Combination Benzoyl Peroxide and Clindamycin
Otic Quinolones
No changes to the current classification of the drug products listed on the Preferred Drug List.

Public Comment

The following persons made comment and answered questions

M. Goetting, MD, Takeda, Rozerem
A. Davis, MD, Genentech, Nutropin
R. Bulten, MD, JNJ, Concerta
N. Alessi, MD, Shire, Vyvanse
J. Goudreau, DO, GSK, Requip XL
L. Carter, PharmD, Jazz Pharma, Luvox CR
L. Quaranta, PharmD, Endo, Voltaren gel

The next Committee meeting is scheduled for Tuesday, December 2, 2008 at 6PM at the Kellogg Center, Michigan State University, East Lansing Michigan

Please bring calendars to schedule the Committee meetings for 2009